Bramante, 6,256 patient metformin prophylaxis study: 7% lower mortality [p=0.15] https://c19p.org/bramante
copied to clipboard
Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis
et al., The Lancet Healthy Longevity, doi:10.1016/S2666-7568(20)30033-7
Retrospective 6,256 COVID-19+ diabetes patients in the USA, showing lower mortality with existing metformin treatment, statistically significant only for women.
|
risk of death, 7.2% lower, RR 0.93, p = 0.15, treatment 394 of 2,333 (16.9%), control 791 of 3,923 (20.2%), NNT 31, odds ratio converted to relative risk, PSM, all patients.
|
|
risk of death, 24.1% lower, OR 0.76, p = 0.02, treatment 1,129, control 2,173, PSM, women, RR approximated with OR.
|
|
risk of death, 3.5% higher, OR 1.03, p = 0.75, treatment 1,204, control 1,750, PSM, men, RR approximated with OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Bramante et al., 12/3/2020, retrospective, database analysis, USA, North America, peer-reviewed, 17 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.